Neither did it appear to be due to repression of the genes encoding the VLA-4 subunits α4 (ITGA4) and β1 (ITGB1) since the expression of these genes was comparable in whole blood samples from untreated and natalizumab-treated MS patients (Figure 1D). Here, ITGA4 is linked to myeloid sarcoma.